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Abstract
Background. SCreening for Occult REnal Disease
(SCORED) is a novel screening guideline recently devel-
oped to identify individuals with a high likelihood of having
prevalent chronic kidney disease (CKD). This simple scor-
ing system, developed from general US representative sam-
ples and independently validated, was shown to outperform
current clinical practice guidelines. Recently, CKD screen-
ing in individuals with cardiovascular disease (CVD) has
been emphasized. We therefore evaluated the SCORED
model in CVD patients in order to better understand the
implications of CKD screening in this population.
Methods. Two clinical trials that enrolled patients with
heart attack (N = 2481) or stroke (N = 3680) were
combined to create our sample. The performance of the
SCORED guideline was evaluated by standard diagnostic
measures. Correlations among various risk scores and their
predictive abilities for recurrent CVD were ascertained.
Results. For heart attack and stroke patients, respectively,
the SCORED guideline yielded sensitivity of 94 and 97%,
specificity of 27 and 11%, positive predictive value of 32
and 30%, negative predictive value of 93 and 89%, with
AUC of 0.75 and 0.68. SCORED was strongly correlated
with other risk scores and exhibited a similar performance
in the prediction of recurrent CVD.
Conclusions. The higher risk of CKD in CVD patients
with high SCORED values is demonstrated. This simple
education and screening tool may help promote awareness
of CKD in CVD patients, in addition to general populations,
and assess the CKD risk and its relationship with recurrent
CVD.
Keywords: CKD; CVD; ENRICHD; VISP
Introduction
Cardiovascular disease (CVD) and chronic kidney disease
(CKD) are each major public health problems that share
risk factors and present in similar populations [1,2]. Yet,
awareness for potential CKD by healthcare professionals
and lay persons remains low among at-risk populations,
including those with CVD. Indeed, a joint science advisory
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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board from the American Heart Association (AHA) and the
National Kidney Foundation (NKF) recently recommended
screening for decreased kidney function among patients
with known CVD [3]. Identifying individuals with CKD
in this population may provide an opportunity to adopt
measures that slow the progression of kidney disease and
prevent subsequent CVD.
We recently developed a user-friendly tool to systemati-
cally identify individuals with a high likelihood of having
CKD, SCreening for Occult REnal Disease (SCORED) [4].
This algorithm identified nine demographic and medical
variables and provided a simple scoring system. SCORED
has been validated in the general population, community
samples and clinical settings; the screening tool also per-
formed favourably compared to the NKF’s Kidney Early
Evaluation Program (KEEP) guidelines [4–6].
We now seek to test SCORED in a population with known
underlying CVD. Our goals are 2-fold: first, we intend to
evaluate test characteristics of SCORED in diverse CVD
patients. Second, we would like to assess correlation of
SCORED with other algorithms suitable for CVD and to
compare their abilities for secondary CVD prediction.
Methods
Study population
We used the data collected from two recent multi-centre, cardiovascu-
lar clinical trials, Enhancing Recovery in Coronary Heart Disease (EN-
RICHD) and Vitamin Intervention for Stroke Prevention (VISP), in our
investigation.
ENRICHD is a randomized controlled trial (RCT), sponsored by the
National Heart, Lung, and Blood Institute, that tested a hypothesis that
a new psychosocial intervention, devised to decrease depression and to
increase social support, further improves a composite endpoint of ‘death
and nonfatal reinfarction’ after acute myocardial infarction (MI) [7]. Over
3000 participants were screened at 73 hospitals affiliated to eight aca-
demic sites in the United States, and 2481 were randomized into cognitive
behaviour therapy or usual cardiology care. The trial was conducted from
1996 to 2001 with an average follow-up of 29 months.
VISP, sponsored by the National Institute of Neurological Disorders and
Stroke, is an RCT undertaken to study the effectiveness of homocysteine-
lowering therapy for recurrent vascular events in patients with non-
disabling stroke [8]. VISP aimed to determine whether high doses of
folic acid, vitamin B6 and vitamin B12, given to lower total homocysteine
levels, further reduce the risk of recurrent stroke over a 2-year period
compared with low doses of these vitamins. A total of 3680 adults with
non-disabling cerebral infarction participated in this study at 56 hospitals
or medical centres across the USA, Canada and Scotland in 1996–2003.
Measurements
The SCORED risk factors, along with additional demographic characteris-
tics, personal health conditions and clinical information at randomization
were retrieved from the databases. Unfortunately, not all variables included
in SCORED were available in these studies. Specifically, peripheral vas-
cular disease information was absent in VISP, anaemia information was
absent in ENRICHD and urinalysis was not conducted in both studies.
For kidney function, we used estimated glomerular filtration rate
(eGFR) from the Modification of Diet in Renal Disease study equation
[9]:
GFR (mL/ min /1.73 m2) = 186∗[serum creatinine (mg/dL)]−1.154∗
[age (years)−0.203]∗[1.212 (ifAfrican American)]∗[0.742 (if female)].
CKD was defined as an eGFR < 60 mL/min/1.73 m2, which corresponds
to stage 3 or higher kidney disease [10]. (Throughout the paper, we will
designate eGFR < 60 mL/min/1.73 m2 as CKD rather than CKD stage
3–5.)
Statistical analyses
Baseline characteristics of the ENRICHD and VISP participants were
summarized by descriptive statistics.
The potential value of SCORED was evaluated by estimating the per-
centage of subjects classified into ‘high risk’ (defined by score ≥4) as
well as standard diagnostic criteria such as sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV) and area under
the receiver-operating-characteristic curve (AUC) [11]. In addition, we
tested a new classification rule for defining a high-risk group as having
at least one CVD risk factor (i.e. hypertension, diabetes, heart failure or
peripheral vascular disease) included in SCORED.
We also fitted the SCORED model to each study. The association
between each risk factor and CKD was summarized in terms of odds ratio,
confidence interval and statistical significance. CKD prevalence by total
score was estimated for general healthy individuals using the National
Health and Nutrition Examination Survey (NHANES), Atherosclerosis
Risk in Communities (ARIC) and Cardiovascular Heart Study (CHS)
(that we used in our previous investigations) and for CVD patients from
ENRICHD and VISP.
Next, Pearson correlation coefficients were calculated among
SCORED and other well known risk scores in ENRICHD because
many of the necessary variables were not available in VISP. Other risk
scores include Charlson comorbidity index (for 10-year survival) [12],
Framingham score (for incident coronary heart disease) [13], Jaffe scores
(one for recurrent MI or mortality and the other for all-cause mortality)
[14] and Stroke Prognosis Instrument (SPI) II (for recurrent stroke or
death) [15]. For prediction, we used ‘recurrent MI or death’ that was the
primary endpoint in ENRICHD and ‘recurrent stroke’ that was the primary
endpoint in VISP. In addition to discrimination, model-fit statistics such
as Akaike and Bayesian information criteria (AIC and BIC) were com-
puted. It is important to evaluate prediction models based on more than
one criterion, especially beyond AUC, as each method addresses different
aspects of prediction [16–19].
All analyses were performed using the SAS version 9.1 statistical soft-
ware. Two-sided hypothesis tests with a 5% type I error were adopted for
all statistical inferences.
Results
A total of 2145 participants from ENRICHD and 3640
participants from VISP were included for analyses after
excluding participants with missing data in key variables.
Participants from VISP were, on average, 5 years older
than participants from ENRICHD. ENRICHD had more
female and minority participants. Notably, the mean eGFR
(75 mL/min/1.73 m2) and the prevalence of CKD (27–28%)
were similar between the two studies (see Table 1).
Prediction of prevalent CKD
In ENRICHD, sensitivity, specificity, PPV and NPV of the
SCORED guideline were estimated to be 94%, 27%, 32%
and 93%, respectively. By this rule, 78% of ENRICHD
participants were defined to be at high risk for CKD. The
application to VISP provided sensitivity of 97%, speci-
ficity of 11%, PPV of 30% and NPV of 89%, while 91% of
VISP participants were defined to be at high risk. The rule
based on the absence versus the presence of CVD risk fac-
tors generally yielded reduced test characteristics, although
SCORED yielded low specificity. As an additional compar-
ison, we used NHANES data from generally healthy indi-
viduals to evaluate three screening rules: SCORED, ‘CVD
risk factors only’ and KEEP (Table 2). Table 3 presents lo-
gistic regression analyses with the SCORED risk factors as
predictors of CKD. Most of the risk factors were statistically
significant, and the age effect was monotone.
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Table 1. Characteristics of study participants in ENRICHD and VISP
ENRICHD VISP
Characteristic (N = 2481) (N = 3680)
Mean (SD) or% Mean (SD) or%
Demographic factors
Age (years) 61 (12.5) 66 (10.8)
Female sex 44 37








Not available 45 (15)
Low-density lipoprotein
cholesterol (mg/dL)
Not available 122 (40)
Triglycerides (mg/dL) Not available 175 (154)
Total cholesterol (mg/dL)a 198 (50) 202 (47)
Hypercholesterolaemiab 59 48
Body mass index (kg/m2) 29 (6) 28 (6)
Diabetes mellitus 33 29
Systolic blood pressure
(mmHg)
124 (19) 141 (19)
Diastolic blood pressure
(mmHg)
70 (11) 78 (10)
Hypertension 61 74




Congestive heart failure 37 5
Current smoking 31 17
Endpoint-related information
Serum creatinine (mg/dL) 1.2 (0.83) 1.1 (0.58)





Sample sizes are reduced for some variables due to missing data.
aIn ENRICHD, total cholesterol was available for 1326 subjects, while
high-density lipoprotein cholesterol and other lipids were not measured
because significant changes were expected for all the lipids in acute
situations.
bHistory or total cholesterol >200 mg/dL. SD = standard deviation.
Figure 1 presents a risk assessment chart for general
healthy adults as well as CVD patients that would be use-
ful for clinicians and lay persons for education and coun-
selling purposes. As the score rises, a quadratic increase
in the risk of CKD is observed in both populations, and
the higher risk for CKD among CVD patients is clearly
demonstrated.
Prediction of recurrent CVD
We found that SCORED and previously validated CVD risk
scores were highly correlated with one another: correlation
coefficients between SCORED and these other risk scores
ranged from 0.58 to 0.75 in ENRICHD (see Table 4). This
is not surprising given that many risk factors included in
these scores are shared or correlated with one another.
Prediction characteristics of SCORED and traditional
CVD risk scores for recurrent CVD events are presented in
Table 5. A total of 505 and 298 participants had the primary
clinical events in ENRICHD and VISP, respectively. Multi-
ple regression with SCORED risk factors yielded AUC of
0.69 for recurrent MI or mortality, while simple regression
with total score from SCORED as a single predictor yielded
AUC of 0.66. Other risk scores showed AUC of 0.67–0.72.
As expected, Jaffe scores demonstrated the best model fits
(with dramatically lower AIC/BIC) as those were devel-
oped from ENRICHD. Notably, impaired renal function
(i.e. creatinine ≥1.3) had the largest risk ratio in Jaffe mod-
els [14]. For recurrent stroke, SCORED and SPI II showed
similar AUC and AIC/BIC. Overall, SCORED, which is a
CKD screening/prediction model, appeared to perform well
in secondary CVD prediction.
Discussion
In this paper, we evaluated the SCORED algorithm in RCT
participants that represent a diverse, multi-ethnic CVD
patient population. Compared to healthy individuals that
we tested in previous publications, greater numbers of in-
dividuals were identified with elevated risk by SCORED.
Specificity was decreased and PPV was increased, while
high sensitivity and NPV and moderate to high AUC val-
ues were maintained.
In the general population, the SCORED model was de-
signed to identify individuals with undiagnosed CKD who
could be referred for further laboratory evaluation and
follow-up tests. We expect that the vast majority of CVD
Table 2. Performance of classification rules in vascular patients (ENRICHD/VISP) and general population (NHANES)
Study Guideline % High risk Sensitivity Specificity PPV NPV
ENRICHD (N = 2145) SCORED 78 94 27 32 93
CVD risk factors onlya 79 91 25 30 88
VISP (N = 3640) SCORED 91 97 11 30 89
CVD risk factors onlya 80 87 23 31 82
NHANES 2003–04 (N = 4298) SCORED 40 95 65 20 99
CVD risk factors onlya 48 89 56 17 98
KEEPb 67 90 35 12 97
Sample sizes are reduced due to missing data.
aHaving at least one CVD risk factor (i.e. hypertension, diabetes, heart failure or peripheral vascular disease) included in the SCORED model.
bKEEP was not evaluated in ENRICHD and VISP because data on a majority of risk factors in KEEP were not collected. Raw data in 2 × 2 tables will
be provided upon request from the 1st author. SCORED was derived from NHANES 1999–2002.
CVD = cardiovascular disease; KEEP = Kidney Early Evaluation Program; NHANES = National Health and Nutrition Examination Survey;
NPV = negative predictive value; PPV = positive predictive value.
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Table 3. SCORED model fitted to ENRICHD (N = 2145) and VISP (N = 3640) studies
ENRICHD (AUC = 0.75) VISP (AUC = 0.68)
Odds ratio Odds ratio
SCORED risk factor (95% confidence interval) P-value (95% confidence interval) P-value
Age
50–59 1.4 (0.98–2.1) 0.067 0.9 (0.6–1.4) 0.63
60–69 3.0 (2.1–4.4) <0.0001 1.7 (1.1–2.4) 0.009
≥70 5.5 (3.8–7.9) <0.0001 3.5 (2.4–5.1) <0.0001
Female 1.5 (1.2–1.9) 0.0001 1.5 (1.3–1.7) <0.0001
Anaemiaa Not available 0.99 (0.7–1.5) 0.96
Hypertension 1.7 (1.3–2.1) <0.0001 1.7 (1.4–2.1) <0.0001
Diabetes 1.7 (1.4–2.2) <0.0001 1.3 (1.1–1.5) 0.004
History of cardiovascular disease Not estimableb Not estimableb
History of heart failure 2.2 (1.7–3.0) <0.0001 1.9 (1.4–2.6) <0.0001
Peripheral vascular disease
(circulation problem in legs)c
1.2 (0.9–1.5) 0.32 Not available
Proteinuria (protein detected in urine) Not available Not available
aAnaemia being treated. bNot estimable because all participants had this condition, i.e., score = 1. cHistory information (e.g. claudication). AUC =
area under the receiver-operating-characteristic curve.
patients will have serum chemistry values performed by
their primary care physicians and/or cardiologists/ neurol-
ogists. We therefore envision the SCORED screening tool
serving purposes other than merely identifying CKD.
First, SCORED was designed as a simple checklist for
patients to learn about their risk for kidney disease. While
a cardiologist may be aware that his/her patient has under-
lying renal disease, that information may not be routinely
communicated to a patient during a typical clinic visit or
phone conversation; alternatively, the cardiologist may in-
appropriately assume that the primary care physician has
already discussed the concomitant renal disease with the pa-
tient. Continued late referral has been reported in not only
primary care settings but also in high-risk patients [20–25].
The SCORED tool is patient-friendly and easy to use; many
high-risk patients may not know what their creatinine is (or
what this measurement means) yet will be able to complete
and understand their SCORED testing. SCORED can em-
power CVD patients to introduce the subject of CKD with
their care providers and motivate themselves to be screened
(e.g. based on their self-assessment using Figure 1 in this
paper).
Second, SCORED can re-emphasize the importance of
early kidney disease to cardiologists, neurologists and pri-
mary care physicians who may not consider small elevations
in creatinine to be significant markers of kidney disease. As
eGFRs are appearing more routinely in laboratory reports,
this phenomenon of under-appreciating creatinine values
should dissipate [20], but SCORED would provide another
way to highlight to care providers that, in certain popu-
lations, even early deteriorations in renal function require
heightened surveillance and, often, concomitant care by a
nephrologist. In general, these duties are managed best by
nephrologists.
There are some limitations to our investigation. Firstly,
the diagnosis of CKD was based on only one determi-
nation of eGFR. More than one measurement over time
is recommended for accurate clinical diagnosis capturing
the ‘chronicity’ definition [10,26]. This is, unfortunately,
Fig. 1. Risk assessment chart for CKD using SCORED: recommended
for use by healthcare providers and lay persons.
a common problem in many epidemiologic studies, RCTs,
and even some clinical settings. Also, eGFR derived from
the MDRD formula might not be optimal, although its util-
ity is regarded as, realistically, the current best definition
for CKD [3,27–30]. Secondly, some variables included in
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Table 4. Correlation coefficients among various risk scores in ENRICHD
SCORED Charlson Framingham Jaffe1 Jaffe2 SPI II
SCORED 1 0.58 0.58 0.68 0.75 0.67
Charlson 1 0.18 0.67 0.63 0.72
Framingham 1 0.37 0.44 0.19
Jaffe1 1 0.95 0.70
Jaffe2 1 0.67
SPI II 1
Charlson comorbidity index (DHoore’s version) = 1∗Pulmonary disease
+ 1∗Rheumatologic disease + 1∗Previous MI + 1∗Prior stroke/TIA +
1∗History of peripheral vascular disease + 1∗Peptic ulcer disease +
1∗History of congestive heart failure + 2∗Diabetes + 2∗Renal insuffi-
ciency + 2∗History of malignancy + 3∗Liver cirrhosis.
Jaffe1 = age in year/10∗0.27 + Previous MI∗0.33 + History of congestive
heart failure∗0.31 + Cerebrovascular disease∗0.35 + Pulmonary∗0.40
+ diabetes∗0.32 + Killip∗0.10 + [Ejection Fraction (EF) <30]∗0.46+
(30 ≤ EF <40)∗0.36+(40 ≤ EF<50)∗0.24 + (creatinine ≥ 1.3)∗0.53 +
Beck’s Depression Inventory∗0.015 + CABG∗−0.30 + Vasodilator/not
ACEI∗0.32;
Jaffe2 = age in year/10∗0.45 + Previous MI∗0.22 + History of conges-
tive heart failure∗0.66 + Cerebrovascular disease∗0.263183 + Pulmonary
disease∗0.451085 + Diabetes∗0.364008 + Killip class∗0.187581 +
(EF < 40)∗0.374599+(Creatinine ≥ 1.3)∗0.851789 + Vasodilator
/not ACEI∗0.361076;
SPI II = 3∗congestive heart failure + 3∗Diabetes + 3∗Previous MI +
2∗(age >70) + 2∗Stroke/not TIA + 1∗Severe hypertension + 1∗Coronary
artery disease.
For Framingham risk score, refer to [13]. Framingham score cannot be
written as a simple numerical expression.
For Framingham score, N = 1259 subjects were used because total choles-
terol was severely missing. Since high-density lipoprotein was not col-
lected in ENRICHD, we assigned 0 (i.e. 50–59 mg/dL) to this variable.
Therefore, caution should be exercised when interpreting results from the
Framingham score.
Mean (standard deviation) for risk scores: SCORED = 5.3 (2.1),
Charlson = 2.2 (2.1), Framingham score = 12.4 (4.2), Jaffe1 = 2.8 (0.77),
Jaffe2 = 3.9 (1.1) and SPI II = 4.4 (3.4).
SPI = Stroke Prognosis Instrument.
SCORED were not available in these datasets, including
proteinuria. However, SCORED has been shown to be ro-
bust to a few missing variables [4,5], and we intentionally
did not impute missing variables in order to reflect real sce-
narios encountered in practice. For example, people may not
know the status of some risk factors, or SCORED can be
implemented using administrative database or retrospective
chart review possibly with limited information [6]. Partic-
ularly, low awareness of proteinuria and less availability of
the associated data have been pointed out and improvement
has been called for [2,5,31–33].
The importance of kidney disease screening, education
and risk factor awareness continue to be emphasized glob-
ally [33–39]. Despite all of these efforts, CKD is still
severely under-recognized and screening is not routinely
conducted either in community settings or among high-risk
individuals such as CVD patients or family members of
end-stage renal disease patients [3,30]. SCORED would
serve as a simple but useful screening and educational tool.
It would be reasonable to encourage the use of SCORED
in community screening settings and to require eGFR and
urinalyses in CVD settings, in keeping with the AHA/NKF
statement, recognizing that almost 80–90% of CVD pa-
tients were classified at high risk for CKD by SCORED.
Moreover, common risk factors may support the develop-
Table 5. Prediction of recurrent CVD events over 2 years by different risk
scores











Charlson 0.67 7296 7300
Jaffe1 0.72 5333 5337
















We used the original primary endpoints of ENRICHD and VISP. Not all
risk scores presented in Table 4 were included in this analysis due to highly
missing covariates for some risk scores. Note that smaller AIC and BIC
indicate a better model fit.
AUC were computed from logistic regression and AIC/BIC were computed
from Cox regression.
AIC = Akaike information criteria; AUC = area under the receiver-
operating-characteristic curve; BIC = Bayesian information criteria.
ment of unified prevention and management strategies for
CVD and CKD.
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